ISFAN
CLSD

Investor's Fiduciary Advisor Network’s Clearside Biomedical CLSD Stock Holding History

Investor's Fiduciary Advisor Network’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,253
Closed -$27K – 238
2025
Q2 		$27K Hold
2,253
– – 0.01% 220
2025
Q1 		$31K Hold
2,253
– – 0.01% 166
2024
Q4 		$32K Buy
+2,253
New +$37K 0.01% 199

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Investor's Fiduciary Advisor Network's CLSD Position: Q3 2025 in Review

Investor's Fiduciary Advisor Network sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 2,253 shares — an estimated $27K sold.

Investor's Fiduciary Advisor Network first reported a position in CLSD in Q4 2024 and held it in 3 quarters. The position peaked at $32K in Q4 2024. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • Investor's Fiduciary Advisor Network reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • Investor's Fiduciary Advisor Network sold 2,253 Clearside Biomedical shares in Q3 2025, an estimated $27K.
  • Investor's Fiduciary Advisor Network first reported a position in Clearside Biomedical in Q4 2024 and held it in 3 quarters.
  • Investor's Fiduciary Advisor Network's Clearside Biomedical position peaked at $32K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on Investor's Fiduciary Advisor Network's 13F filing for Q3 2025, filed 3 Nov 2025.